News & Videos - BRAIN BIOTECNA O.N. - English

EQS-News: BRAIN Biotech AG / Key word(s): Quarterly / Interim Statement BRAIN Biotech AG: 3M FY 24/25 - Starting the year with double digit sales growth in the core BRAINBiocatalysts division 26.02.2025 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. BRAIN Biotech AG: 3M FY 24/25 - Starting the year with double digit sales growth in the core BRAINBiocatalysts division BRAINBiocatalysts organic growth at 11 % in Q1 Quantitative guidance looking at strong...

EQS-News: BRAIN Biotech AG / Key word(s): Alliance/Sustainability Biological gold recycling: BRAIN Biotech AG collaborates with PX Group on the PX Urban Mining Initiative 13.02.2025 / 09:14 CET/CEST The issuer is solely responsible for the content of this announcement. Biological gold recycling: BRAIN Biotech AG collaborates with PX Group on the PX Urban Mining Initiative Development of BioXtractor V2 pilot by BRAIN and PX Group and production of first BioGold nuggets from a local waste stream...

EQS-News: BRAIN Biotech AG / Key word(s): Annual Report/Annual Results Annual Report 2023/24: BRAIN Biotech AG acts from a strong cash position and is confident about its growth prospects 15.01.2025 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Annual Report 2023/24: BRAIN Biotech AG acts from a strong cash position and is confident about its growth prospects Group cash and cash equivalents improved to € 27.2 million Successfully closed two milestone...

EQS-News: BRAIN Biotech AG / Key word(s): Capital Markets Day BRAIN Biotech AG Sharpens Focus on Profitable Growth 12.12.2024 / 09:00 CET/CEST The issuer is solely responsible for the content of this announcement. BRAIN Biotech AG Sharpens Focus on Profitable Growth Combination of BioProducts segment and BioScience Zwingenberg to form the growth segment BRAINBiocatalysts Five-year targets in the BRAINBiocatalysts segment: revenues of EUR 100 million, 15 % adjusted EBITDA margin and high R&D...

EQS-News: BRAIN Biotech AG / Key word(s): Contract BRAIN Biotech AG and Akribion Therapeutics GmbH sign exclusive pharma licensing agreement for G-dase E® CRISPR-Cas technology 31.10.2024 / 19:20 CET/CEST The issuer is solely responsible for the content of this announcement. BRAIN Biotech AG and Akribion Therapeutics GmbH sign exclusive pharma licensing agreement for G-dase E ® CRISPR-Cas technology Akribion Therapeutics GmbH financed by strong Venture Capital Consortium with pharma expertise...

EQS-Ad-hoc: BRAIN Biotech AG / Key word(s): Contract BRAIN Biotech AG signs exclusive pharma licensing agreement for G-dase E® CRISPR-Cas technology with Akribion Therapeutics GmbH for up to EUR 92.3 million milestone fees plus royalties 31-Oct-2024 / 19:11 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. NOT FOR...

EQS-News: BRAIN Biotech AG / Key word(s): Personnel Prof. Dr. Wiltrud Treffenfeldt leaves Supervisory Board of BRAIN Biotech AG for personal reasons 03.10.2024 / 14:00 CET/CEST The issuer is solely responsible for the content of this announcement. Prof. Dr. Wiltrud Treffenfeldt leaves Supervisory Board of BRAIN Biotech AG for personal reasons Zwingenberg, Germany, October 03, 2024 – Professor Dr. Wiltrud Treffenfeldt has informed the Chairman and the other members of the Supervisory Board of...

EQS-News: BRAIN Biotech AG / Key word(s): Contract BRAIN Biotech AG concludes major pharma compound transaction valued up to EUR 128.88 million from its BioIncubator 20.09.2024 / 19:50 CET/CEST The issuer is solely responsible for the content of this announcement. BRAIN Biotech AG concludes major pharma compound transaction valued up to EUR 128.88 million from its BioIncubator Total transaction value up to EUR 128.88 million significantly exceeding current market capitalization of BRAIN Biotech...

EQS-Ad-hoc: BRAIN Biotech AG / Key word(s): Contract BRAIN Biotech AG concludes royalty monetization deal for up to EUR 128.88 million on investigational pharma compound deucrictibant with Royalty Pharma 20-Sep-2024 / 19:47 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. NOT FOR DISTRIBUTION OR DISSEMINATION, DIRECTLY...

EQS-News: BRAIN Biotech AG / Key word(s): 9 Month figures/Quarterly / Interim Statement BRAIN Biotech AG presents strong cash position with its 9M reporting and is forecasting good sequential growth in the final quarter of the business year 29.08.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. BRAIN Biotech AG presents strong cash position with its 9M reporting and is forecasting good sequential growth in the final quarter of the business year Cash...

EQS-News: BRAIN Biotech AG / Key word(s): Personnel BRAIN Biotech AG announces the appointment of Erik de Vries as Senior Business Development Director Enzymes 29.05.2024 / 09:00 CET/CEST The issuer is solely responsible for the content of this announcement. BRAIN Biotech AG announces the appointment of Erik de Vries as Senior Business Development Director Enzymes Zwingenberg and Greifswald, May 29, 2024 – BRAIN Biotech AG and Enzymicals AG are pleased to announce that Dr. Erik de Vries will...

EQS-News: BRAIN Biotech AG / Key word(s): Half Year Results/Half Year Report BRAIN Biotech AG receives major milestone payment and stays on-track to achieve year end targets 28.05.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. BRAIN Biotech AG receives major milestone payment and stays on-track to achieve year end targets Major milestone payment from pharma-project of € 1.5 million received BioProducts business growth accelerated in Q2, further...

EQS-News: BRAIN Biotech AG / Key word(s): Miscellaneous BRAIN Biotech AG takes next step to optimize group structure 16.04.2024 / 11:20 CET/CEST The issuer is solely responsible for the content of this announcement. BRAIN Biotech AG takes next step to optimize group structure BRAIN Biotech Group will merge AnalytiCon Discovery GmbH into BRAIN Biotech AG in order to further optimize and simplify the Group structure. Zwingenberg, Germany, 16 April 2024 – The Management Board of BRAIN Biotech AG,...

EQS-News: BRAIN Biotech AG / Key word(s): Alliance/Sustainability Beverages made from vine leaves: Sustainable drinking pleasure based on agricultural side streams 14.03.2024 / 09:00 CET/CEST The issuer is solely responsible for the content of this announcement. Beverages made from vine leaves: Sustainable drinking pleasure based on agricultural side streams BRAIN Biotech, Tropical Viticulture Consultants, Zukunftsweine and Provadis Hochschule jointly develop sustainable, non-alcoholic beverages...

EQS-News: BRAIN Biotech AG / Key word(s): AGM/EGM Results of the Annual General Meeting 2024 for the financial year 2022/23 of BRAIN Biotech AG 12.03.2024 / 17:17 CET/CEST The issuer is solely responsible for the content of this announcement. Results of the Annual General Meeting 2024 for the financial year 2022/23 of BRAIN Biotech AG Face-to-face event at the Zwingenberg site Executive Board and Supervisory Board approved by a clear majority Silent partnership with the State of Hesse approved...

EQS-News: BRAIN Biotech AG / Key word(s): Alliance/Sustainability Collaboration between BRAIN Biotech and AMSilk: Protein engineering successfully improves structural proteins for performance materials 05.03.2024 / 08:00 CET/CEST The issuer is solely responsible for the content of this announcement. Collaboration between BRAIN Biotech and AMSilk: Protein engineering successfully improves structural proteins for performance materials First patent application registered BRAIN Biotech relies on...

EQS-News: BRAIN Biotech AG / Key word(s): Bond BRAIN Biotech AG successfully placed EUR 5.0 million convertible bond for the financing of further growth initiatives 29.02.2024 / 20:40 CET/CEST The issuer is solely responsible for the content of this announcement. BRAIN Biotech AG successfully placed EUR 5.0 million convertible bond for the financing of further growth initiatives Zwingenberg, Germany, 29 February 2024 – At its meeting today and with the approval of the Supervisory Board, the...

EQS-Ad-hoc: BRAIN Biotech AG / Key word(s): Bond BRAIN Biotech AG: Issuance of EUR 5 million convertible bond with exclusion of subscription rights 29-Feb-2024 / 20:06 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. NOT FOR DISTRIBUTION OR DISSEMINATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA,...

EQS-News: BRAIN Biotech AG / Key word(s): Quarterly / Interim Statement 3M FY 23/24: BRAIN Biotech looks optimistic to stay on the growth path for fiscal year 2023/24 28.02.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. 3M FY 23/24: BRAIN Biotech looks optimistic to stay on the growth path for fiscal year 2023/24 Strong BioScience business in Q1 BioProducts growth to accelerate over the next quarters Optimistic outlook for the business year targeting...

EQS-News: BRAIN Biotech AG / Key word(s): Annual Report/Annual Results Annual Report 2022/23: BRAIN Biotech AG successfully executes growth strategy 17.01.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Annual Report 2022/23: BRAIN Biotech AG successfully executes growth strategy Group sales grew by 11.8 %, 9.8 % all organic All divisions contribute to growth Successful execution of One-BioProducts strategy Strong progress on BioIncubator...